Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
暂无分享,去创建一个
Lihong Shi | Petro Halkowycz | D. Dougan | Shawn M. O’Connell | Lihong Shi | Douglas R. Dougan | Xianchang Gong | Qing Dong | Petro Halkowycz | Bohan Jin | Toufike Kanouni | Nicholas Scorah | Michael B. Wallace | Feng Zhou | Q. Dong | Toufike Kanouni | N. Scorah | Xianchang Gong | Bohan Jin | Fenger Zhou | M. B. Wallace
[1] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[2] S. Shuto,et al. Alternative synthesis of cyclic IDP-carbocyclic ribose. Efficient cyclization of an 8-bromo-N1-[5-(phosphoryl)carbocyclic-ribosyl]inosine 5′-phenylthiophosphate derivative mediated by iodine , 1999 .
[3] R. Hamatake,et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. , 2009, Cancer research.
[4] J. Lyssikatos,et al. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. , 2005, Current topics in medicinal chemistry.
[5] J. Lyssikatos,et al. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. , 2006, Journal of medicinal chemistry.
[6] Rongshi Li,et al. Kinase Inhibitor Drugs , 2009 .
[7] J. Warmus,et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.
[8] G. Piccialli,et al. Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support , 2008 .
[9] Shuto,et al. An efficient synthesis of cyclic IDP- and cyclic 8-bromo-IDP-carbocyclic-riboses using a modified Hata condensation method to form an intramolecular pyrophosphate linkage as a key step. An entry to a general method for the chemical synthesis of cyclic ADP-ribose analogues , 2000, The Journal of organic chemistry.
[10] J. Warmus,et al. 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase). , 2008, Bioorganic & medicinal chemistry letters.
[11] N. Dumaz,et al. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways , 2005, The FEBS journal.
[12] C. Der,et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer , 2009, Molecular Cancer Therapeutics.
[13] Laura M. Heiser,et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.
[14] J. Sebolt-Leopold,et al. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. , 2002, Trends in molecular medicine.
[15] E. Krebs,et al. The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] J. Lyons,et al. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.
[17] C. Sander,et al. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.
[18] G. Robertson,et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. , 2006, Cancer research.
[19] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[20] S. Barrett,et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. , 2007, Arthritis and rheumatism.
[21] S. Mu,et al. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker , 2009, Clinical Cancer Research.
[22] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[23] Daniel F Ortwine,et al. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. , 2007, Journal of medicinal chemistry.
[24] A. Doherty,et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. , 2008, Bioorganic & medicinal chemistry letters.
[25] J. Settleman,et al. Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.